Sign in or Register   Sign in or Register
  |  

Mouse Anti-CDA Recombinant Antibody (921CT14.2.1) (CBMAB-C4871-CQ)

This product is a mouse antibody that recognizes CDA. The antibody 921CT14.2.1 can be used for immunoassay techniques such as: WB.
See all CDA antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
921CT14.2.1
Antibody Isotype
IgG1
Application
WB

Basic Information

Immunogen
Purified His-tagged CDA protein
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Concentration
0.35 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Cytidine Deaminase
Introduction
CDA (Cytidine Deaminase) is a Protein Coding gene. Diseases associated with CDA include Refractory Hematologic Cancer and Refractory Hairy Cell Leukemia. Among its related pathways are Pyrimidine metabolism (KEGG) and Innate Immune System. Gene Ontology (GO) annotations related to this gene include protein homodimerization activity and hydrolase activity.
Entrez Gene ID
978
UniProt ID
P32320
Alternative Names
Cytidine Deaminase; Cytidine Aminohydrolase; CDD; Cytosine Nucleoside Deaminase; Small Cytidine Deaminase; EC 3.5.4.5;
Function
This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.
Biological Process
Cell surface receptor signaling pathway Source: UniProtKB
Cytidine deamination Source: UniProtKB
Cytosine metabolic process Source: UniProtKB
Negative regulation of cell growth Source: UniProtKB
Negative regulation of nucleotide metabolic process Source: UniProtKB
Neutrophil degranulation Source: Reactome
Pyrimidine-containing compound salvage Source: UniProtKB
Pyrimidine nucleoside salvage Source: Reactome
Cellular Location
Cytosol; Extracellular region; Ficolin-1-rich granule lumen; Secretory granule lumen; Tertiary granule lumen

Frances, A., & Cordelier, P. (2020). The emerging role of cytidine deaminase in human diseases: a new opportunity for therapy?. Molecular Therapy, 28(2), 357-366.

Bjånes, T. K., Jordheim, L. P., Schjøtt, J., Kamceva, T., Cros-Perrial, E., Langer, A., ... & Riedel, B. (2020). Intracellular cytidine deaminase regulates gemcitabine metabolism in pancreatic cancer cell lines. Drug Metabolism and Disposition, 48(3), 153-158.

Murakami, Y., Kimura, Y., Kawahara, A., Mitsuyasu, S., Miyake, H., Tohyama, K., ... & Kuwano, M. (2019). The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes. Oncotarget, 10(23), 2270.

Liu, W., Shang, F., Chen, Y., Lan, J., Wang, L., Chen, J., ... & Xu, Y. (2019). Biochemical and structural analysis of the Klebsiella pneumoniae cytidine deaminase CDA. Biochemical and biophysical research communications, 519(2), 280-286.

Moro-Bulnes, A., Castillo-Acosta, V. M., Valente, M., Carrero-Lérida, J., Pérez-Moreno, G., Ruiz-Pérez, L. M., & González-Pacanowska, D. (2019). Contribution of cytidine deaminase to thymidylate biosynthesis in trypanosoma brucei: intracellular localization and properties of the enzyme. Msphere, 4(4), e00374-19.

Peters, G. J., Giovannetti, E., Honeywell, R. J., & Ciccolini, J. (2019). Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?. British journal of clinical pharmacology, 85(6), 1213.

Cohen, R., Preta, L. H., Joste, V., Curis, E., Huillard, O., Jouinot, A., ... & Blanchet, B. (2019). Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. British journal of clinical pharmacology, 85(6), 1227-1238.

Fanciullino, R., Farnault, L., Donnette, M., Imbs, D. C., Roche, C., Venton, G., ... & Costello, R. (2018). CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. Blood Advances, 2(5), 462-469.

Rajabpour, A., Afgar, A., Mahmoodzadeh, H., Radfar, J. E. D., Rajaei, F., & Teimoori-Toolabi, L. (2017). MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells. Cancer chemotherapy and pharmacology, 80(4), 765-775.

Corrie, P., Qian, W., Gopinathan, A., Williams, M., Brais, R., Valle, J. W., ... & Jodrell, D. (2017). Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC). Annals of Oncology, 28, v251-v252.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CDA Recombinant Antibody (921CT14.2.1)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare